Daiichi Sankyo Europe Highlights Broad EAS Congress 2026 Data Presentations Supporting Patient-Centred Cardiovascular Care Daiichi Sankyo Europe has announced a major scientific presence at the upcoming European Atherosclerosis Society Congress 2026, highlighting the company’s continued commitment to advancing cardiovascular care…
Hologic Showcases New ASCO 2026 Data Highlighting the Role of the Breast Cancer Index® Test in Guiding Extended Endocrine Therapy Decisions Hologic and its subsidiary Biotheranostics have announced new clinical data showing how the Breast Cancer Index® (BCI™) Test is…
SAGA Diagnostics Highlights NeoCircle Publication Showcasing Prognostic Impact of ctDNA Dynamics in Early Breast Cancer SAGA Diagnostics has announced the publication of new clinical research highlighting the potential of ultrasensitive circulating tumor DNA (ctDNA) monitoring to transform the management of…
BeOne Medicines Showcases More Than 60 Abstracts at ASCO and EHA 2026 BeOne Medicines announced that it will present more than 60 scientific abstracts at two of the world’s most influential oncology and hematology conferences in 2026, reinforcing the company’s…
Inocras Presents Real-World Evidence Supporting Whole-Genome HRD Profiling in Ovarian Cancer Treatment Inocras, a bioinformatics-driven precision oncology company specializing in whole-genome sequencing and advanced genomic analytics, has announced that new clinical findings evaluating whole-genome sequencing-based homologous recombination deficiency (HRD) phenotyping…
BeOne Medicines Showcases Expanding Oncology Pipeline With More Than 60 Presentations at ASCO and EHA 2026 BeOne Medicines Ltd. has announced a major presence at two of the world’s leading oncology conferences in 2026, highlighting the company’s rapidly expanding influence…
Merck Secures CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has…
ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) make treatment decisions following BCG therapy…
Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care Natera announced an extensive oncology research program for the 2026 Annual Meeting of the American Society of Clinical Oncology, underscoring the company’s…
Acuitas Therapeutics Showcases In Vivo CAR T Engineering and Lipid Innovations at ASGCT 2026 Acuitas Therapeutics concluded a prominent showing at the American Society of Gene & Cell Therapy 2026 Annual Meeting with the presentation of new research focused on…
Savara Inc. Reports Sustained Efficacy and Favorable Safety Findings from the Ongoing IMPALA-2 Phase 3 Open-Label Extension Study of Molgramostim in aPAP Patients Savara Inc. announced the presentation of new long-term efficacy and safety findings from its ongoing Phase 3…
Sensome Reports Encouraging First-in-Human Clinical Results for Its Innovative In Situ Lung Tumor Detection Technology Sensome has announced positive results from its first-in-human INSPECT clinical study evaluating the company’s microsensor-enabled smart stylet technology for bronchoscopic lung biopsy procedures. According to…